CommercialAdministrativeLow impact
Ocriplasmin for Symptomatic Vitreomacular Adhesion
Blue Cross & Blue Shield of Mississippi·MS · Ophthalmology·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a policy review with no changes - BCBS MS confirmed their existing coverage policy for ocriplasmin (Jetrea) remains unchanged, covering single intravitreal injections for symptomatic vitreomacular adhesion/traction. Note that ocriplasmin manufacturing was discontinued in the US since 2020, making this largely academic.
Action Required
No immediate action required - this is a policy review with no changes. The drug remains discontinued in the US since 2020, so billing scenarios are unlikely. If encountered, verify patient meets eligibility criteria including OCT demonstration of vitreous adhesion within 6mm of fovea and visual acuity of 20/25 or worse.